Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels?

Journal of Clinical Laboratory Analysis

Volumn 24, Issue 4, 2010, Pages 273-277

  Kiyici, Aysel ^a   Mehmetoǧlu, Idris ^a   Karaoǧlan, Hatice ^a   Atalay, Hüseyin ^b   Solak, Yalçin ^b   Türk, Süleyman ^b  

^a Selc uk Universitesi   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

Author keywords

Bromocresol green; Bromocresol purple; End stage renal disease; Hemodialysis; Ischemia Modified albumin

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BROMCRESOL PURPLE; BROMOCRESOL GREEN; C REACTIVE PROTEIN; CREATININE; ISCHEMIA MODIFIED ALBUMIN; UREA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COLORIMETRY; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; TECHNIQUE; UREA NITROGEN BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; BROMCRESOL GREEN; BROMCRESOL PURPLE; COHORT STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 77955593060     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20399     Document Type: Article

References (33)

1. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - A preliminary report. J Emer Med 2000;19:311-315.
2. Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischaemia and myocardial infarction. Clin Chem 2003;49:581-585.
3. Bar-Or D, Lau E, Rao N, Bampos N, Winkler JV, Curtis CG. Reduction in the cobalt-binding capacity of human albumin with myocardial ischaemia. Ann Emer Med 1999;34:S56.
4. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253-262. (Pubitemid 44093396)
5. Troxler M, Thompson D, Homer-Vanniasinkam S. Ischaemic skeletal muscle increases serum ischaemia modified albumin. Eur J Vasc Endovasc Surg 2006;31:164-169. (Pubitemid 43078944)
6. Abboud H, Labreuche J, Meseguer E, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007;23:216-220.
7. Turedi S, Gunduz A, Mentese A, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emer Med 2007;25:770-773. (Pubitemid 47385040)
8. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113-114. (Pubitemid 43021873)
9. Şeneş M, Kazan N, Coşkun O, Zengi O, Inan L, Yücel D. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007;44:43-47. (Pubitemid 46168800)
10. Valle Gottlieb MG, da Cruz IB, Duarte MM, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2010;95:586-591. Epub 2009 Dec 16.
11. Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010;43:450-454.
12. Jia ZT, Liu CY, Li H. Changes of the concentration of serum ischemia modified albumin and high sensitivity C-reactive protein in type 2 diabetic patients with retinopathy. Zhonghua Yan Ke Za Zhi 2009;45:805-808.
13. Wong CK, Szeto CC, Chan MH, Leung CB, Li PK, Lam CW. Elevation of pro-inflammatory cytokines, C-reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. Immunol Invest 2007;36:47-57.
14. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;53:2129-2140.
15. Zapico-Muniz E, Santalo-Bel M, Merce-Muntanola J, Montiel JA, Martinez-Rubio A, Ordonez-Llanos J. Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 2004;50:1063-1065. (Pubitemid 38725798)
16. van der Zee PM, Verberne HJ, van Straalen JP, et al. Limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischaemia. Clin Chem 2005;51:1744-1746.
17. Gaze DC, Crompton L, Collinson P. Ischaemia-modified albumin concentrations should be interpreted with caution in patients with low serum albumin concentrations. Med Princ Pract 2006;15:322-324. (Pubitemid 43876749)
18. Lee YW, Kim HJ, Cho YH, Shin HB, Choi TY, Lee YK. Application of albumin-adjusted ischaemia modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta 2007;384:24-27.
19. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischaemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007;45:261-262. (Pubitemid 46294690)
20. Wells FE, Addison GM, Postiethwaite RJ. Albumin analysis in serum of haemodialysis patients: discrepancies between bromocresol purple, bromocresol green and electroimmunoassay. Ann Clin Biochem 1985;22:304-309.
21. Mabuchi H, Nakahashi II. Underestimation of serum albumin by the bromocresol purple method and a major endogenous ligand in uremia. Clin Chim Acta 1987;167:89-96. (Pubitemid 17147612)
22. Beyer C, Boekhout M, van Iperen H. Bromocresol purple dye-binding and immunoturbidimetry for albumin measurement in plasma or serum of patients with renal failure. Clin Chem 1994;40:844-845. (Pubitemid 24142868)
23. Carfray A, Patel K, Whitaker P, Garrick P, Griffiths GJ, Warwick GL. Albumin as an outcome measure in haemodialysis in patients: The effect of variation in assay method. Nephrol Dial Transplant 2000;15:1819-1822.
24. Parikh C, Yalavarthy R, Gurevich A, Robinson A, Teitelbaum I. Discrepancies in serum albumin measurements vary by dialysis modality. Ren Fail 2003;25:787-796. PMID: 14575287. (Pubitemid 37187673)
25. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493-502. (Pubitemid 43255184)
26. Sharma R, Gaze DC, Pellerin D, et al. Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease. Clin Sci 2007;113:25-32. (Pubitemid 47066022)
27. Cichota LC, Moresco RN, Duarte MMF, da Silva JEP. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008;22:1-5. (Pubitemid 351272474)
28. Carrega L, Giaime P, Montserrat C, et al. Influence of the dialysis membrane on markers of tissue ischemia. J Investig Med 2006;54:62-66. (Pubitemid 43352488)
29. Malindretos P, Sarafidis PA, Rudenco I, et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol 2007;27:572-579. (Pubitemid 350014944)
30. MontagnanaM, Lippi G, Tessitore N, et al. Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal 2008;22:59-65. (Pubitemid 351272482)
31. Lowrie EG, Lew NL. Death risk in haemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-482.
32. Turley CP, Andries LA, Arnold WA. Dye binding and electrophoretic techniques compared for albumin assay in hypoalbumenic sera. Clin Chem 1985;31:336-337.
33. Leerunck CB, Winckers EKA. Multilayer-film bromocresol green method for albumin measurement significantly inaccurate when albumin/globulin ratio is <0.8[Letter]. Clin Chem 1991;37:766-767.